Baillie Gifford & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baillie Gifford & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-82	Closed	-$8.49K	–	456
2022 Q4	$8.49K	Hold	82	–	–	﹤0.01%	423
2022 Q3	$7K	Hold	82	–	–	﹤0.01%	428
2022 Q2	$7K	Hold	82	–	–	﹤0.01%	435
2022 Q1	$6K	Hold	82	–	–	﹤0.01%	457
2021 Q4	$7K	Hold	82	–	–	﹤0.01%	464
2021 Q3	$6K	Hold	82	–	–	﹤0.01%	474
2021 Q2	$7K	Hold	82	–	–	﹤0.01%	448
2021 Q1	$6K	Buy	82 +8	+11%	+$654	﹤0.01%	427
2020 Q4	$6K	Buy	+74	New	+$5.87K	﹤0.01%	410
2013 Q4	–	Sell	-5,949	Closed	-$430K	–	209
2013 Q3	$430K	Hold	5,949	–	–	﹤0.01%	180
2013 Q2	$332K	Buy	+5,949	New	+$371K	﹤0.01%	155

Other funds holding BMRN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Baillie Gifford & Co's BMRN Position: Q1 2023 in Review

Baillie Gifford & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 82 shares — an estimated $8.49K sold.

Baillie Gifford & Co first reported a position in BMRN in Q2 2013 and held it in 11 quarters. The position peaked at $430K in Q3 2013. 551 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

Baillie Gifford & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Baillie Gifford & Co sold 82 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $8.49K.
Baillie Gifford & Co first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Baillie Gifford & Co's BioMarin Pharmaceuticals position peaked at $430K in Q3 2013.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Baillie Gifford & Co's 13F filing for Q1 2023, filed 3 May 2023.